Daiwa analyst Narumi Nakagiri upgraded Eli Lilly (LLY) to Buy from Neutral with a $1,230 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Bank of America Says Market Isn’t Pricing in Eli Lilly’s (LLY) Weight-Loss Drug Dominance
- NVDA, LLY, AMD, PODD, DIS: Top 5 Strong Buy “Growth Stocks” for 2026
- Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs
- Eli Lilly price target lowered to $1,268 from $1,286 at BofA
- Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating